Advertisement

Canadian Journal of Public Health

, Volume 91, Issue 5, pp 366–370 | Cite as

Drug Resistance Study of Mycobacterium tuberculosis in Canada, February 1, 1993 to January 31, 1994

  • Ezzat FarzadEmail author
  • Donna Holton
  • Richard Long
  • Mark FitzGerald
  • Adalbert Laszlo
  • Howard Njoo
  • Anne Fanning
  • Earl Hershfield
  • Vernon Hoeppner
  • Edward Allen
Article

Abstract

Objective: To estimate the prevalence of resistance of Mycobacterium tuberculosis to first-line antituberculosis drugs in Canada.

Methods: M. tuberculosis isolates from one third of all culture-positive tuberculosis (TB) cases diagnosed between February 1, 1993 to January 31, 1994 in Canada were collected prospectively. Proportion of drug-resistant isolates and the factors related to drug resistance were measured.

Results: Of 458 study cases, 40 (8.7%) had resistance to at least one first-line antituberculosis drug, of which 5–9% had mono-resistance, 0.7% had multidrug-resistance(MDR-TB) — i.e., resistance to at least isoniazid and rifampin — and 2.2% had other patterns. The overall prevalence of resistance among the foreign-born cases was 10.6% with the highest level among those who resided in Canada for less than four years (15.5%).

Conclusions: Canada has a relatively low prevalence of antituberculosis drug resistance and a very low prevalence of MDR-TB. Some new immigrants to Canada may be at higher risk for drug resistance and their initial treatment needs to be tailored accordingly.

Résumé

Objectif: Évaluer la prévalence de la résistance du mycobacterium tuberculosis contre le médicament antituberculeux de première ligne au Canada.

Méthodes: Le mycobacterium tuberculosis repère un tiers de tous les cas de cultures tuberculosis qui ont fait l’objet d’un diagnostic positif entre le 1er février 1993 et le 31 janvier 1994 au Canada; ces données ont été collectées de manière prospective. On a mesuré la proportion de repère des médicaments résistants et les facteurs reliés à la résistance du médicament.

Résultats: Sur 458 cas étudiés, 40 (8,7 %) se sont avérés résistants à au moins un médicament antituberculeux de première ligne dont 5,9 % se sont avérés résistants à un seul médicament et 0,7 % ont une résistance à plusieurs médicaments (MDR-TB) — c.-à-d. résistants à au moins deux médicaments: l’isoniazid et le rifampin — et 2,2 % avaient d’autres caractéristiques. La prévalence globale de la résistance parmi les cas venus de l’étranger était de 10,6 % dont le niveau le plus élevé a résidé au Canada pendant moins de quatre ans (15,5 %).

Conclusions: Au Canada, la prévalence de la résistance des médicaments antituberculeux est relativement faible. Certains nouveaux arrivants peuvent présenter un risque plus élevé de résistance aux médicaments et leur traitement initial doit être personnalisé en conséquence.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Antituberculosis Drug resistance in the World, The WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance 1994–1997, WHO 1997.Google Scholar
  2. 2.
    Edlin BR, Tokars JL, Grieco MH, et al. An outbreak of multidrugresistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514–21.CrossRefGoogle Scholar
  3. 3.
    Frieden T, Sterling T, Pablos-Méndez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521–26.CrossRefGoogle Scholar
  4. 4.
    Monno L, Angarano G, Carbonara S, et al. Emergence of drug resistant Mycobacterium tuberculosis in HIV-infected patients. Lancet 1991;337:852.CrossRefGoogle Scholar
  5. 5.
    Herrera D, Cano R, Godoy P, et al. Multidrugresistant tuberculosis outbreak on an HIV ward-Madrid, Spain, 1991–1995. MMWR 1996;45:330–33.Google Scholar
  6. 6.
    Eidus L, Jessamine AG, Hershfield ES, Helbecque DM. A national study to determine the prevalence of drug resistance in newly discovered previously untreated tuberculosis patients as well as in retreatment cases. Can J Public Health 1978;69:146–53.PubMedGoogle Scholar
  7. 7.
    Long R, Fanning A, Cowie R, et al., and the Western Canadian Tuberculosis Group. Antituberculous drug resistance in western Canada. Can Respir J 1997;4(2):71–75.CrossRefGoogle Scholar
  8. 8.
    Long R, Manfreda J, Mendella L, et al. Antituberculous drug resistance in Manitoba from 1980 to 1989. CMAJ 1993;148:1489–95.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Manns BJ, Fanning EA, Cowie RL. Antituberculosis drug-resistance in immigrants to Alberta, Canada, with tuberculosis, 1982–1994. Int J Tuberc Lung Dis 1997;1(3):225–30.PubMedGoogle Scholar
  10. 10.
    Kochi A, Vareldzis B, Styblo K. Multidrug resistant tuberculosis and its control. Res Microbiol 1993;144:104–10.CrossRefGoogle Scholar
  11. 11.
    Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527–32.CrossRefGoogle Scholar
  12. 12.
    Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. JAMA 1993;270:65–68.CrossRefGoogle Scholar
  13. 13.
    Canadian Tuberculosis Standards, Fourth Edition, Canadian Lung Association, 1996.Google Scholar
  14. 14.
    Tuberculosis in Canada, 1996, Health Canada.Google Scholar
  15. 15.
    Statistics Canada. Causes of Death, 1995, catalogue number 84-208-XPB, Ministry of Industry, Ottawa, Canada, 1997.Google Scholar
  16. 16.
    Tuberculosis Statistics, 1990, Statistics Canada.Google Scholar
  17. 17.
    Laszlo A, Gill P, Handzel V, et al. Conventional and radiometric drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 1983;18:1335–39.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Case Notification Update, 1996, Global Tuberculosis Program, World Health Organization, Geneva.Google Scholar
  19. 19.
    Tuberculosis Statistics, 1993, Statistics Canada.Google Scholar
  20. 20.
    Rivest P, Tannenbaum T, Bédard L. Epidemiology of tuberculosis in Montreal. CMAJ 1998;158:605–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Hersi A, Elwood K, Cowie R, et al. Multidrugresistant tuberculosis in Alberta and British Columbia 1989 to 1998. Can Respir J 1999;6:155–60.CrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 2000

Authors and Affiliations

  • Ezzat Farzad
    • 1
    Email author
  • Donna Holton
    • 2
  • Richard Long
    • 3
  • Mark FitzGerald
    • 4
  • Adalbert Laszlo
    • 5
  • Howard Njoo
    • 6
  • Anne Fanning
    • 7
  • Earl Hershfield
    • 8
  • Vernon Hoeppner
    • 9
  • Edward Allen
    • 10
  1. 1.Division of Blood Borne PathogensLCDCOrleansCanada
  2. 2.Regina Health DistrictReginaCanada
  3. 3.Department of MedicineUniversity of AlbertaEdmontonCanada
  4. 4.TB Services to AboriginalsBC Centre for Disease Control SocietyVancouverCanada
  5. 5.A/Head National Reference Centre for Tuberculosis, LCDCConsultant TB Bacteriology-International Union Against Tuberculosis and Lung Disease (IUATLD)OttawaCanada
  6. 6.Division of Tuberculosis Prevention and ControlLCDCCanada
  7. 7.Department of MedicineUniversity of AlbertaCanada
  8. 8.Department of MedicineUniversity of ManitobaWinnipegCanada
  9. 9.Department of MedicineUniversity of SaskatchewanSaskatoonCanada
  10. 10.University of British ColumbiaCanada

Personalised recommendations